INSULIN DELIVERY DEVICES MARKET ANALYSIS

Insulin Delivery Devices Market - Insights

Insulin is vital for people suffering from type 1 diabetes and type 2 diabetes. Preciously, patients with diabetes had to inject insulin using large glass syringes and reusable needles, both of which needed sterilization by boiling after each use. Improvements and innovations has led to development of insulin delivery devices such as pens and insulin pumps. Furthermore, insulin analogs have become available that enable both continuous subcutaneous insulin infusion (CSII) using an insulin pump and insulin therapy using multiple daily injections (MDI) to more closely match physiologic insulin patterns. Type or dosage of insulin can be changed, to meet the individual needs of the patient. Insulin can be packaged in vials (bottles), cartridges or prefilled pens. The cartridges are used with pen injectors whereas the vials are used with syringes.

The global insulin delivery devices market was valued at US$ 11,326.9 million in 2017 and is expected to witness a CAGR of 11.3% over the forecast period (2017–2025).

Figure 1. Global Insulin Delivery Devices Market Share, By Product Type (%)

To learn more about this report, request sample copy

Source: Coherent Market Insights Analysis (2017)

Increasing prevalence of diabetes is expected to drive growth of the global insulin delivery devices market over the forecast period

Increasing prevalence and incidence of diabetes is a major factor driving the global insulin delivery devices market growth. According to the Centers for Disease Control and Prevention (CDC), 2014, around 29.1 million people in the U.S. have diabetes with a healthcare burden of around US$ 245 Bn and with an estimated 4.6–9.2% of pregnant women affected by gestational diabetes. Moreover, the Australian government launched National Diabetes Strategy (2016–2020), to prevent diabetes and support people living with diabetes. Thus, increasing government initiatives to support diabetic patients is expected to favor growth of the global insulin delivery devices market.

Development of systems and devices for improved drug delivery is expected to drive growth of the market. When compared with vial and syringe regimens, insulin pens offer a greater clinical efficacy, improved quality of life, and increased dosing accuracy, particularly at low doses. Thus, introduction of insulin pen devices has aided patients with diabetes mellitus in easier and more convenient treatment regimens. For instance, in January 2014, Novo Nordisk launched the NovoPen Echo in the U.S. market. This is the first and only pen device available in the U.S. with half-unit dosing and a memory function that can record the dose and time passed since the last injection.

Increasing adoption of advanced devices for insulin delivery is driving growth of the market

Increasing awareness among population regarding insulin delivery devices coupled with high demand for insulin administration for diabetes control are expected to drive growth of the market. Among regions, in 2017, North America, accounted for largest share in global insulin delivery devices market, followed by Europe, owing to high prevalence of lifestyle associated diseases, implementation of awareness programs regarding diabetes, and high adoption of advanced medical devices. For instance, in 2010, according to Journal of Diabetes Science and Technology, majorly insulin pumps were used on the American side of the Atlantic than on the European side, which is projected to propel demand for insulin pumps over the forecast period.

Furthermore, in 2016, the UAE Ministry of Health and Prevention in partnership with the Emirates Diabetes Society and Ministry with AstraZeneca Gulf, launched Circle of Care, an education and support program, which intends to improve the well-being of people in the UAE suffering from or at risk of developing type 2 diabetes, in turn fueling growth of the market over the forecast period.

Key players in the market are focusing on developing next generation devices to remain competitive, while seeking ways to enhance their design capabilities. For instance, in October 2017, Eli Lilly and Company announced its plans to invest US$ 72 million in an insulin manufacturing project at one of its Indianapolis, U.S. facilities. The investment will be used to replace an existing insulin vial filling line and allow the company to meet growing demand for its insulin - including Humalog (insulin lispro) and Humulin (human insulin) - while upgrading to state-of-the-art technology and preparing for its insulin pipeline.